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Genetics SelectThe complete human genome sequence presents researchers with unique opportunities not only for identifying the
mechanisms underlying a battery of genetic diseases but also for revealing what makes us human. This issue’s Genetics
Select highlights recent developments in the field of human genetics that promise to direct future studies in the fields of
comparative genomics and human disease research.
Humans, Your Genes Are Numbered
Genomics-scale analyses are now used to study evolution, comparative genetics, and human disease. As such analyses
become more common, proper annotation of protein-coding genes will be essential, and a tough challenge is making this
determination on a genome-wide basis. It is not feasible to tackle this problem experimentally gene by gene, and assigning
labels based on sequence conservation is difficult. In a new study, Clamp et al. (2007) address this challenge by establishing
criteria to define protein-coding genes in the human genome, and they develop a computational protocol that enables them to
rapidly classify human genes according to their genomic characteristics. Current catalogs consider the presence of open
reading frames (ORFs) to be indicative of a protein-coding gene, even if the sequence is not conserved in other mammals.
Thismode of thinking predicts that human evolution necessitated the advent of new genes. Through a newmethod of genome
analysis, Clamp et al. reject this practice, proposing that nonconserved, or orphan, ORFs might arise randomly during geno-
mic evolution. Indeed, their analysis suggests that theremight be only 168 human-specific protein-coding genes in the human
genome. This new methodology trims the calculated number of human protein-coding genes from 24,500 to 20,500 and
establishes criteria for future evaluation of putative human protein-coding genes. The authors suggest that areas of the
genome that have not been adequately annotated, especially those regions encoding short polypeptides or containing non-
coding genes, where marked changes might be more readily observed, are ripe areas for future study. Overall, the new work
indicates surprisingly that relatively little genomic innovation might have occurred during human evolution. Importantly, the
genomics algorithm used in this study should be readily applicable to other sequenced genomes.
M. Clamp et al. (2007). Proc. Natl. Acad. Sci USA 104, 19428–19433.
Splicing Creates a Species Distinction
The differences between humans and chimpanzees, although visually striking, are
relatively small on a genomic scale. Although chimpanzees are our closest relatives,
we display many species-specific morphological, immunological, and behavioral
differences. How are these differences established? Certainly some genes are ex-
pressed differentially, but in most cases, the same protein products are produced,
leading to only slight alterations in cellular signaling events. Conversely, alternative
splicing provides a framework for marked diversification in protein expression pro-
files. To determine the extent of alternative splicing differences between humans
and chimps, Calarco et al. (2007) used a strategy that coupled comparative genomics
with microarray profiling. They found that 6%–8% of orthologous exons display
substantial differences in alternative splicing; these changes showed little overlap
with differentially expressed genes, suggesting that different layers of regulation exist
to modulate protein expression between the two species. Splicing changes appeared
to arise from nucleotide substitutions in cis-acting splicing elements as well as from
expression changes in specific splicing factors; indeed, the splicing factor SRp40 is
itself differentially spliced in the two species. Interestingly, these changes in alternative splicing affect a diverse set of proteins
whose biological functions range from overall gene regulation to the immune response. Splicing changes were also detected
in proteins whose dysfunction has been implicated in human disease, for example, splicing changes in the glutathione trans-
ferase Gsto2 might contribute to Alzheimer’s disease etiology. These preliminary results suggest that in examining alternative
splicing differences between human and nonhuman primates (and also between humans and mice, the most frequently used
genetic model organism), we might gain much-needed insight into human-specific molecular events, both normal and dis-
ease-related.
J.A. Calarco et al. (2007). Genes Dev. 21, 2963–2975.
Evolution in Fits and Spurts
Although most human genes are highly conserved, human genomic architecture is more complex than in most other species,
including most nonhuman primates. The human genome harbors many areas indicative of recent duplication events. These
duplications, often large highly similar stretches of DNA, are interspersed throughout the genome. They can underlie numerous
genomic alterations leading to polymorphisms and copy number variation aswell as genetic innovation.Why do these differen-
ces exist between human and nonhuman primates, and how do they influence human genetics? Jiang et al. (2007) addressed
these questions by analyzing genome-wide human segmental duplications. They note that whereas some chromosomes con-
tain relatively fewstructural differencescompared toothermammalian species,othersdisplayextensive intrachromosomal (and
less frequently interchromosomal) duplications. Their results suggest that such duplications might have served as ‘‘seeding’’
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events for further genomic rearrangements that triggered important evolutionary events. Indeed, the majority of such duplica-
tionsoccurred following thesplit ofhumansandchimpanzees fromthemacaque lineage.Asubset of thesechanges, focal points
for genomic restructuring, are termed core duplicons; these core duplicons contain a greater than expected number of genes
andexpressedsequence tags (ESTs). Strikingly, thecorescontain rapidlyevolvingandhighlydivergent genesandgene families;
several show evidence of significant selective pressure. The importance and the functions of these genetic loci remain incom-
pletely understood. Future studies, however, should reveal further clues about the unique nature of the human genome and the
influence that these loci had on specific evolutionary paths. The new work indicates that extensive and nonrandom structural
changes underlie human-specific genomic innovation, including the expansion of new gene families. These same regions are
creating genomic instability that predisposes toautism,mental retardation, anddevelopmental delay in humans. Although these
changes account for a relatively small portion of the human genome, they might have driven tremendous evolutionary change.
Z. Jiang et al. (2007). Nat. Genet. 39, 1361–1368.
Measuring Meiotic Crises
Although alterations in protein expression are contributing factors for many human diseases, several diseases also result from
meiotic recombinationdefects that generate structural changes,duplications, deletions, or inversions in thegenome.Asubsetof
meiotic errors arises from nonallelic homologous recombination (NAHR) events that drive copy number variation of dosage-
sensitive genes. Several NAHR loci are associated with two diseases: one resulting from a duplication and the other from the
reciprocal deletion event, e.g., Charcot-Marie-Tooth disease type 1A (CMT1A, duplication) and hereditary neuropathy with lia-
bility to pressure palsies (HNPP, deletion) at 17p11.2-12. The frequency of such events is inherently difficult to measure, and in
somecasesonlypathogenicdeletioneventshavebeen identified.The reason for thisdiscrepancy iscurrently unknown:perhaps
someduplication eventsmight cause verymild defects and therefore never be clinically ascertained; conversely, someduplica-
tion eventsmight cause such severe defects that they are never observed; or duplicationsmight occur less frequently than their
seemingly reciprocal deletion events. However, healthy individuals harbor an approximately equivalent proportion of nonpatho-
genicduplicationanddeletionevents. Toaddress thisquestion,Turner etal. (2007)developedabreakpoint-specificPCR-based
assay that can accurately detect and discernNAHR duplication and deletion events. Using pooled human sperm samples, they
analyzed the meiotic error rate at four NAHR disease hotspots. At each breakpoint, duplications and deletions were identified;
surprisingly, in each case, deletions occurred at a higher rate than duplications. Moreover, the different hotspots display signif-
icant differences in recombination frequency, suggesting that the underlying genetic architecture directs disease etiology. Why
shouldpathogenicdeletionsarisemore frequently?Thisquestion remainsopen.Nevertheless, this study suggests that although
deletions and duplications can be reciprocal events, the rates of such changes need not be equivalent. Overall, these findings
indicate that we have much to learn about understanding, detecting, and diagnosing diseases with known or suspected NAHR
involvement. Encouragingly, this assay seems well suited for the clinic and so could be valuable for genetic counseling.
D.J. Turner et al. (2007). Nat. Genet. 40, 90–95.
Taking Charge on the Genetics Superhighway
At the time of clinical presentation, the tumors of human cancer patients contain numerous
mutations, often numbering in the tens of thousands. Some mutations cause aberrations that
promote cancer initiation or progression, so-called driver mutations. However, recent data indi-
cate that some clonal mutations in tumors lack apparent function. These changes have been
termed passenger mutations, and if improperly categorized, they can create numerous compli-
cations for clinicians and cancer researchers. Although whole-genome sequencing can identify
the landscape of genetic changes that occur within a tumor, the challenge lies in identifying driver
mutations that are the targets for therapeutic intervention. Acute myelogenous leukemia (AML)
patients often harbor mutations in the tyrosine kinase growth factor receptor FLT3. Although
manymutations are known to promote promiscuous kinase activity, in other cases the functional
consequences of themutations remain unknown. Fro¨hling et al. (2007) sequenced the FLT3 gene
in leukemic cells derived from 222 AML patients and characterized the identifiedmutations using
a variety of cellular and biochemical assays. Through their screen, they identified four new can-
didate driver mutations whose activity could promote leukemogenesis, along with five passen-
ger mutations that had no effect on FLT3 function. These results caution that although a specific
gene is implicated in cancer, it can harbor mutations that do not influence cancer progression.
More importantly, high-throughput DNA sequencing promises to be a powerful tool to identify
relevant disease genes, and it seems likely that its use will drive further research into a variety
of diseases for which causative mutations remain elusive. As an increasing number of studies
identify risk alleles, this techniquewill be valuable in locating drivers while dismissing passengers
and in directing the next steps in disease research.
S. Fro¨hling et al. (2007). Cancer Cell 12, 501–513.
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